StockMarketWire.com - Evgen Pharma confirmed it would deliver the read-out of its Phase II clinical trial of its metastatic breast cancer treatment 'early next week.'

The company also confirmed that the treatment phase of its breast cancer drug trial had now concluded with the final read-out expected in later summer 2019.

The company delivered an update on two Phase II clinical trial of its metastatic breast cancer treatment, SFX-01.

'The final read-out of the STEM trial in metastatic breast cancer is expected to be announced early next week, in line with the Company's earlier guidance of Q1 2019,' the company said.

The treatment phase of the trial (SAS) of SFX-01 in subarachnoid haemorrhage, had now concluded with the last patient on the trial having received the final patient dose, the company added.

The SAS trial would remain fully blinded until all of the secondary endpoint data had been collected, with the final read-out expected in late summer 2019.

'This is a hugely exciting time for Evgen as we build up to the read-out early next week of our Phase II clinical trial of SFX-01 in metastatic breast cancer. These results are expected to be followed in the late summer this year by the final read-out of our SAS Phase II trial of SFX-01 in subarachnoid haemorrhage,' said Steve Franklin, CEO of Evgen Pharma.

'Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time. By doing this, we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies. This approach will maximise the commercial value of the dataset from the SAS trial.'




At 9:11am: [LON:EVG] Evgen Pharma Plc share price was +2p at 17.25p



Story provided by StockMarketWire.com